Literature DB >> 24353782

Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report?

F Giancola1, G Campisi1, L Lo Russo2, L Lo Muzio2, O Di Fede1.   

Abstract

Entities:  

Year:  2013        PMID： 24353782      PMCID： PMC3860225     

Source DB:  PubMed          Journal:  Ann Stomatol (Roma)        ISSN： 1824-0852


× No keyword cloud information.
  3 in total

Review 1.  Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.

Authors:  David Lebwohl; Ozlem Anak; Tarek Sahmoud; Judith Klimovsky; Ingrid Elmroth; Tomas Haas; Joseph Posluszny; Stephen Saletan; William Berg
Journal:  Ann N Y Acad Sci       Date:  2013-05-09       Impact factor: 5.691

2.  Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer.

Authors:  Valentina Guarneri; David Miles; Nicholas Robert; Véronique Diéras; John Glaspy; Ian Smith; Christoph Thomssen; Laura Biganzoli; Tanya Taran; PierFranco Conte
Journal:  Breast Cancer Res Treat       Date:  2010-04-02       Impact factor: 4.872

3.  Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone.

Authors:  C Christodoulou; A Pervena; G Klouvas; E Galani; M E Falagas; G Tsakalos; A Visvikis; A Nikolakopoulou; V Acholos; G Karapanagiotidis; E Batziou; D V Skarlos
Journal:  Oncology       Date:  2009-02-12       Impact factor: 2.935
  3 in total
  9 in total

1.  Osteonecrosis of the jaw associated with ziv-aflibercept.

Authors:  Hani Mawardi; Peter Enzinger; Nadine McCleary; Reshma Manon; Alessandro Villa; Nathaniel Treister; Sook-Bin Woo
Journal:  J Gastrointest Oncol       Date:  2016-12

2.  The Prevention of Medication-related Osteonecrosis of the Jaw.

Authors:  Philipp Poxleitner; Monika Engelhardt; Rainer Schmelzeisen; Pit Voss
Journal:  Dtsch Arztebl Int       Date:  2017-02-03       Impact factor: 5.594

3.  Osteonecrosis of the jaw associated with everolimus: A case report.

Authors:  Daigo Yamamoto; Yu Tsubota; Toshiki Utsunomiya; Noriko Sueoka; Aiko Ueda; Kayoko Endo; Katsuhiro Yoshikawa; Masanori Kon
Journal:  Mol Clin Oncol       Date:  2016-12-05

Review 4.  Medication-Related Osteonecrosis of the Jaw: New Insights into Molecular Mechanisms and Cellular Therapeutic Approaches.

Authors:  Thomas Lombard; Virginie Neirinckx; Bernard Rogister; Yves Gilon; Sabine Wislet
Journal:  Stem Cells Int       Date:  2016-09-18       Impact factor: 5.443

5.  A Case of Pentastomiasis at the Left Maxilla Bone in a Patient with Thyroid Cancer.

Authors:  Eunae Sandra Cho; Seung Wook Jung; Hwi-Dong Jung; In Yong Lee; Tai-Soon Yong; Su Jin Jeong; Hyun Sil Kim
Journal:  Korean J Parasitol       Date:  2017-08-31       Impact factor: 1.341

Review 6.  Osteonecrosis of the jaw in the era of targeted therapy and immunotherapy in oncology.

Authors:  Antonio Fabrizio Nifosì; Mariateresa Zuccarello; Lorenzo Nifosì; Vanessa Hervas Saus; Gianfilippo Nifosì
Journal:  J Korean Assoc Oral Maxillofac Surg       Date:  2019-02-26

Review 7.  The impact of sex steroids on osteonecrosis of the jaw.

Authors:  Ranhee Kim; Sung Woo Kim; Hoon Kim; Seung-Yup Ku
Journal:  Osteoporos Sarcopenia       Date:  2022-06-17

Review 8.  Review and update on drugs related to the development of osteonecrosis of the jaw.

Authors:  A Eguia; L Bagán-Debón; F Cardona
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2020-01-01

Review 9.  Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates.

Authors:  L Lorusso; L Pieruzzi; M Gabriele; M Nisi; D Viola; E Molinaro; V Bottici; R Elisei; L Agate
Journal:  J Endocrinol Invest       Date:  2021-07-21       Impact factor: 4.256
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.